RankAlpha logo
Back to Rankings

IMMX

Immix BiopharmaA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The cleanest bull argument is that enrollment completion has turned IMMX from a vague pipeline story into a dated Q3 2026 readout setup, while the year-end cash balance and expected CIRM support reduce immediate financing pressure into that catalyst window [#8-K-2026-03-30] [#10-K-2026-03-25].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -7.1.
What can break
CIRM grant support is milestone-based and subject to compliance and disbursement conditions, so reimbursement timing is not fully in management control [#10-K-2026-03-25].
Momentum
84
Value
41
Sentiment
61
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $15.00 · Bear $4.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $13.00
Why
Momentum84 · Δ7d -7.1
Value41 · Δ7d +0.1
Sentiment61 · Δ7d -2.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.1
Δ21d
-11.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
61
33% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
+14.9
Why this grade

Composite grade A. Momentum 83.6 / Value 41.1 / Sentiment 61.1

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$455.15M
Beta
0.31
Shares Out
52.15M
P/E (TTM) · Derived
-11.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-17.11
Rev YoY
-
EPS YoY
+2.2%
Gross Margin
-
Op Margin
-
Net Debt
-$17.68M
Current Ratio
1.53
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology